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Purpose. To evaluate corneal thickness changes during pulsed accelerated corneal cross-linking (CXL) for keratoconus using a new
isotonic riboflavin formula.Methods. In this prospective, interventional, clinical study patientswith grades 1-2 keratoconus (Amsler-
Krumeich classification) underwent pulsed accelerated (30mW/cm2) CXL after application of an isotonic riboflavin solution (0.1%)
with HPMC for 10 minutes. Central corneal thickness (CCT) measurements were taken using ultrasound pachymetry before and
after epithelial removal, after riboflavin soaking, and immediately after completion of UVA treatment. Results. Twenty eyes of
11 patients (4 males, 7 females) were enrolled. Mean patient age was 26 ± 3 (range from 18 to 30 years). No intraoperative or
postoperative complications were observed in any of the patients. Mean CCT was 507 ± 35 𝜇m (range: 559–459 𝜇m) before and
475 ± 40 𝜇m (range: 535–420 𝜇m) after epithelial removal (𝑃 < 0.001). After 10 minutes of riboflavin instillation, there was a
statistically significant decrease of CCTby 6.2% from 475±40 𝜇m(range: 535–420 𝜇m) to 446±31 𝜇m(range: 508–400) (𝑃 < 0.005).
There was no other statistically significant change of CCT during UVA irradiation. Conclusions. A significant decrease of corneal
thickness was demonstrated during the isotonic riboflavin with HPMC application while there was no significant change during
the pulsed accelerated UVA irradiation.
1. Introduction
Corneal cross-linking (CXL) is a minimally invasive proce-
dure that combines the use of riboflavin and ultraviolet-A
(UVA) irradiation resulting in an increase of the biomechani-
cal stability of the corneal tissue [1, 2]. A preoperative corneal
thickness of 400 𝜇m as a minimum safety limit to avoid
corneal endothelial damage during CXL has been proposed
[3]. However, endothelial failure has been reported very
occasionally after CXL resulting in corneal edema postop-
eratively [4, 5]. The etiology of such problems has not been
fully elucidated but may be due to severe stromal thinning
intraoperatively which has been reported by several authors
[6, 7]. Hence, it has become important to monitor corneal
thickness during the procedure.
Accelerated CXL is based on the Bunsen-Roscoe law
of reciprocity according to which reducing irradiation time
and correspondingly increasing irradiation intensity could
achieve the same photochemical effect.
The aim of this study was to evaluate the intraoperative
pachymetric changes during CXL using isotonic riboflavin
(0.1%) and HPMC (hydroxyl propyl methylcellulose, HPMC;
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2. Materials and Methods
In this prospective, interventional, clinical study patientswith
grades 1-2 keratoconus (Amsler-Krumeich classification)
were enrolled. All patients underwent pulsed high intensity
CXL using theKXL system (Avedro Inc.,Waltham,MS,USA)
preceded by the application of an isotonic riboflavin (0.1%)
and HPMC (hydroxyl propyl methylcellulose, HPMC; VibeX
Rapid, Avedro Inc.,Waltham,MS, USA) for 10minutes at Eye
Care Center, Maadi, Cairo, Egypt, between August 2014 and
February 2015. The study was conducted within the tenets of
the Declaration of Helsinki after obtaining the institutional
review board approval. A written informed consent was
obtained from all patients.
Inclusion criteria were progressive keratoconus (pro-
gression was confirmed if there was an increase in the
𝐾max on Pentacam maps of 1.00 diopter [D], increase of
manifest refraction cylinder of 1.00D, or increase of manifest
refraction spherical equivalent of 0.50D over the period of
one year) and corneal thickness more than 400𝜇m at the
thinnest location. Exclusion criteria were corneal scars or
opacities, pregnancy or lactation, active anterior segment
pathologic features, previous corneal or anterior segment
surgery, systemic connective tissue disease, atopic syndrome,
and dry eye syndrome. Preoperative data obtained from the
case records included patient age and gender, Pentacam cen-
tral corneal thickness (CCT) and thinnest corneal thickness
(TCT) values, and CCT values obtained by ultrasonic corneal
pachymetry (Sonomed 300P PacScan Pachymeter; Escalon
Medical Corp.), which takes the mean of 256 measurements
in each scan.
2.1. Surgical Technique. Corneal cross-linking (CXL) was
conducted under sterile conditions. One drop of pilocarpine
1% eye drops was instilled 15 minutes before the procedure.
After topical application of benoxinate hydrochloride 0.4%
eye drops (Benox; Eipico Inc., Cairo, Egypt), an eye speculum
was placed and CCT was measured just before epithelial
removal. The probe tip of the ultrasonic pachymetry was
disinfected using alcohol swab and was held perpendicular to
the cornea. Three consecutive measurements were obtained
at the center of the cornea of each eye; the thinnest measure-
ment is used in the statistical analysis.Then, the central 8mm
of the corneal epithelium was removed mechanically using
a blunt spatula. After corneal epithelial removal, CCT was
measured. Next, dextran-free riboflavin 0.1% with hydroxyl
propyl methylcellulose (HPMC; VibeX Rapid, Avedro Inc.,
Waltham, MS, USA) was instilled every 2 minutes for 10
minutes after whichCCTwas remeasured. Pulsed accelerated
UVA irradiation was next performed using KXL system
(Avedro Inc., Waltham, MS, USA) with 1 sec. on/1 sec. off
of UVA irradiation of 30mW/cm2 for a total duration of
8 minutes and 40 seconds. A final CCT measurement was
obtained immediately after completion of UVA irradiation. A
therapeutic contact lens was applied and removed at the 3rd
postoperative day after complete reepithelialization.
2.2. Statistical Analysis. Statistical analysis was done using















































Figure 2: CCT changes (in microns) during UVA treatment.
Because both eyes of some patients were used in the
study, a nested analysis of variance was used to correct for
any correlation between the right and left eyes of the same
subject. 𝑃 value less than 0.05 was considered significant.
3. Results
Twenty eyes of 11 patients were included. Four were males
and 7 were females. Mean patient age was 26 ± 3 (range
from 18 to 30 years). No intraoperative or postoperative
complications were observed in any of the patients.
Mean USP CCT was 506.85 ± 35.4 𝜇m (range: 559–
459 𝜇m) before and 474.9 ± 39.75 𝜇m (range: 535–420𝜇m)
after epithelial removal (𝑃 < 0.001). After 10 minutes of
riboflavin installation, there was a statistically significant
decrease of CCT by 6.2% (31.95 ± 8.08 𝜇m) from 474.9 ±
39.75 𝜇m (range: 535–420𝜇m) to 445.7 ± 31.18 𝜇m (range:
508–400𝜇m) (𝑃 < 0.005) (Figure 1). There was no statisti-
cally significant change of the CCT during UVA irradiation;
CCT was 444.65 ± 34.53 𝜇m (range: 521–400𝜇m) at the end
of UVA irradiation (𝑃 = 0.61) (Figure 2). However, there
was a statistically significant decrease by 62.2 ± 34.64 𝜇m
in CCT from 506.85 ± 35.4 𝜇m (range: 559–459 𝜇m) before
epithelial removal to 444.65 ± 34.53 𝜇m (range: 521–400𝜇m)
at the end of CXL (𝑃 < 0.001). Results are summarized in
Table 1.
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445.7 ±31.18 508 400
USP CCT
after UVA 444.65 ±34.53 521 400
CCT: central corneal thickness, USP: ultrasound pachymetry, and UVA:
ultraviolet.
4. Discussion
Several studies have already reported the intraoperative
corneal thickness changes during the CXL procedure using
several riboflavin formulas and different UVA settings. Most
of the studies evaluated the classic Dresden protocol accord-
ing to which riboflavin-dextran solution was applied for 30
minutes followed by 30 minutes of UVA 3mW/cm2. Thus,
Kymionis et al. reported a 20% decrease in CCT after 30
minutes of riboflavin instillation [6]. Mazzotta and Carag-
iuli observed 32% decrease after 30 minutes of riboflavin-
dextran solution instillation; at 10 minutes of the 30-minute
instillation procedure the CCT decrease was almost 18%
[7]. Hassan et al. showed 23.76% decrease after 15 minutes
of riboflavin application [8]. They all reported no corneal
thickness changes during UVA treatment [6–8]. However,
Tahzib et al. showed stable CCT values after riboflavin
solution instillation, whichmight be attributed to the fact that
they removed the eye speculum during riboflavin application
[9]. Soeters et al. indicated that avoidance of an eyelid
speculum during riboflavin instillation resulted in less CCT
reduction [10].
The use of isotonic riboflavin solution without dextran
has been suggested to avoid the dehydrating effect of dextran
on the corneal stroma. Çinar et al. showed swelling of
the cornea instead of corneal thinning after 30 minutes
of isotonic riboflavin solution without dextran during CXL
procedure [11]. In a comparative study, Oltulu et al. evaluated
the corneal thickness changes during CXL performed with
isotonic riboflavin solution with and without dextran; the use
of riboflavin solution without dextran during CXL caused a
steady increase in the corneal thickness during the procedure
[12]. Recently, Jain et al. demonstrated no significant decline
in the corneal thickness after CXL using isotonic riboflavin
with HPMC with accelerated CXL [13].
In this clinical study, an isotonic dextran-free riboflavin
formula with HPMC (HPMC; VibeX Rapid, Avedro Inc.,
Waltham, MS, USA) was used in combination with pulsed
accelerated UVA using the KXL system (Avedro Inc.,
Waltham, MS, USA). The addition of HPMC to 0.1%
riboflavin aims to avoid the dehydrating effect of dextran
while maintaining adequate concentration of riboflavin into
the stroma through its viscosity. After 10minutes of riboflavin
solution instillation, there was a statistically significant
decrease of CCT by 6.2% (31.95±8.08 𝜇m) from 475±40 𝜇m
(range: 535–420𝜇m) to 446 ± 31 𝜇m (range: 508–400𝜇m).
There was no other statistically significant change of the CCT
during UVA irradiation.
It seems that there was a lesser reduction of CCT in
our study compared to previous studies in which riboflavin
with dextran was used [7–9]. In the study of Jain et al., no
significant difference was found after 20 minutes of isotonic
riboflavin with HPMC [13]. However, they did not perform
pachymetry measurement at 10 minutes of the 20-minute
UVA irradiation process [13]. In our study, we performed
a 10-minute riboflavin instillation process and a 6.2% CCT
decrease was measured after 10 minutes of isotonic riboflavin
with HPMC instillation. In any case, it seems that isotonic
riboflavin with HPMC may lead to a significant decrease
in the corneal thickness during the instillation process of
the CXL procedure, but less than the decrease reported
in previous studies using riboflavin-dextran solution [6–8].
Therefore, this riboflavin formula might be actually safer
for CXL especially for keratoconic patients with borderline
preoperative corneal thickness (near to 400𝜇m).
Potential limitations of the study included the small
sample size, the fact that repeated central corneal thickness,
measured by ultrasound pachymetry, is strongly affected by
exact centration of the probe on cornea on each measure-
ment, and the fact that the gradient of thickness variation is
strong particularly in keratoconic corneas. Taking into con-
sideration that each scanwith the Sonomed 300P pachymeter
takes themean of 256measurements, 3 scans were performed
with the thinnest measurement (the lowest mean of 256
measurements) in an attempt to respect the safety aspect
during planning or conduction of the procedure.
Pentacam or AS-OCT is much better for corneal thick-
ness assessment than ultrasound pachymetry, especially
when a two-dimensional surface is to be analyzed for the
thinnest point, but in our study, it was not possible to use the
Pentacam intraoperatively for measurements after epithelial
removal, after riboflavin, and after UVA exposure as the
procedure was performed under aseptic techniques in the
operation theater while the Pentacam device is not portable.
Repeated transfer of the patient between the operating theater
and the investigation unit was judged not feasible due to
patient discomfort, the potential risk of contamination, and
corneal dehydration.
Preoperative Pentacam CCT values were recorded but
were not used instead of the preoperative contact pachymetry
CCT values to avoid the bias of using one measurement
device preoperatively and another type of measurement
device intraoperatively.
In conclusion, a significant corneal pachymetric decrease
was demonstrated after 10 minutes of isotonic riboflavin
with HPMC instillation during pulsed accelerated CXL. This
decrement was less than the reduction observed in previous
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studies using riboflavin-dextran solution [7–9]. There was
no corneal thickness change during pulsed accelerated UVA
irradiation. These findings suggest that isotonic riboflavin
with HPMCmight be useful in CXL treatment of keratoconic
patients with thin corneas. Further randomized controlled
trials with larger sample sizes are needed to validate these
observations.
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Caca, “Intraoperative corneal thickness measurements during
corneal collagen cross-linking with isotonic riboflavin solution
without dextran in corneal ectasia,” Cutaneous and Ocular
Toxicology, vol. 33, no. 1, pp. 28–31, 2014.
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